Related Experiment Videos
[Second primary cancers after small-cell lung cancer]
J C Soria1, J M Bréchot, B Lebeau
1Service de pneumologie, Hôtel-Dieu, Paris, France.
Bulletin Du Cancer
|August 1, 1997
Summary
Second primary malignancies (SPMs) occurred in patients with small cell lung cancer (SCLC). These secondary cancers, including lung and other types, significantly impacted survival, with median survival of 6 months for synchronous and 4 months for metachronous SPMs.
Area of Science:
- Oncology
- Pulmonology
- Cancer Epidemiology
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy.
- Understanding the risk and patterns of second primary malignancies (SPMs) in SCLC survivors is crucial for long-term management.
Purpose of the Study:
- To investigate the incidence and types of second primary malignancies (SPMs) in patients diagnosed with small cell lung cancer (SCLC).
- To analyze the survival outcomes associated with synchronous (SSPM) and metachronous (MSPM) second primary malignancies in SCLC patients.
Main Methods:
- Retrospective review of medical records for 1,371 patients with small cell lung cancer (SCLC) treated between 1983 and 1994.
- Identification and classification of synchronous (SSPM) and metachronous (MSPM) second primary malignancies.
- Survival analysis following the diagnosis of SPMs.
Main Results:
- Eight synchronous SPMs (SSPMs) and 8 metachronous SPMs (MSPMs) were identified.
- SSPMs included non-small cell lung cancer (6 patients), head and neck cancer (1), and esophageal cancer (1). Median survival post-SSPM diagnosis was 6 months.
- MSPMs, diagnosed 1-6 years post-SCLC, included lung cancer (3), gastrointestinal malignancies (2), hematologic malignancy (1), prostate cancer (1), and head and neck cancer (1). Median survival post-MSPM diagnosis was 4 months.
Conclusions:
- The occurrence of second primary malignancies (SPMs) represents a notable clinical pattern in small cell lung cancer (SCLC) survivors.
- Potential contributing factors for SPM development include tobacco use, genetic predispositions, and the effects of multimodality cancer treatments.
- SPMs are associated with poor prognosis in SCLC patients, underscoring the need for vigilant long-term surveillance and research into underlying mechanisms.